January 20, 2021 For Immediate Release Contact:media@norml.org Cannabis Use Associated with Reduced Alcohol Intake Among Treatment-Seeking Drinkers Cannabis use is...
Receives Funding From Nextfifty Initiative for Hotline DENVER, DECEMBER 5, 2020 --NextFifty Initiative has awarded Leaf 411 funding towards operationalcosts...
FOR IMMEDIATE RELEASE A Free Virtual Educational Event for Veterans Curious about Cannabis DENVER, NOVEMBER 15, 2020 -- In the...
November 09, 2020 For Immediate Release Contact:media@norml.org Gallup: Record Percentage of Americans Say “Marijuana Should Be Made Legal” Nearly seven-in-ten...
“In light of the current state of COVID-19 and the CDC’s actions, Americans for Safe Access has been monitoring the situation to make sure that medical cannabis patients are not forgotten,” said ASA Founder and President Steph Sherer. We want to ensure that dispensaries are seen as essential businesses that will remain open for patients. We applaud states that have already put emergency precautions into action and we will keep patients and the public updated on any future developments through our http://www.safeaccessnow.org/COVID-19 response page.”
PRESS RELEASE – IMMEDIATE RELEASE Chester Springs, Pennsylvania -Affinity Bio Partners, LLC, a global clinical research organization focused on Medical...
PRESS RELEASE – IMMEDIATE RELEASE Chester Springs, Pennsylvania --(BUSINESS WIRE)—Affinity Bio Partners, LLC, a global clinical research organization focused on...
” Privy Peach, a women-centric CBD brand based out of Colorado, is excited to announce the re-release of their highly sought after intimate oil with increased CBD content just in time for Valentine’s Day. The Privy Peach intimate oil is now available with 50 mg more of CBD for a total of 300mg for the same price of the previous offering (12 pouches instead of 10).”
MEDIA CONTACT: Foundation for an Informed Texas Jax Finkel, Executive Director (512) 785-4602 ExecutiveDirector@informedtexas.org FOR IMMEDIATE RELEASE Monday, November 26th,...
“SciCann Therapeutics and FSD Pharma announce selection of Affinity Bio Partners as the Clinical Research Organization in connection with Compassionate Care Certification Centers to launch the first clinical research study for Irritable Bowel Syndrome (IBS) in Pittsburgh, PA.”